Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study

Figures & data

Figure 1. Patient disposition. NOTES: Three patients provided informed consent but did not have baseline data; hence, 104 patients were enrolled, but 101 comprised the safety analysis set. Reasons for discontinuation were not systematically collected, and the reasons are therefore unknown in some cases. Patients may have discontinued for more than one reason.

Table 1. Summary of demographics and baseline characteristics (safety analysis set).

	α-Blockertreatment naïve^an = 75	α-Blockertreatmentexperienced^an = 26	Total n = 101
Age, mean (SD) years	64.5 (9.7)	66.8 (8.4)	65.1 (9.4)
Range	43–83	49–82	43–83
Daily dose of solifenacin, n (%)
10 mg	42 (56.0)	10 (38.5)	52 (51.5)
5 mg	33 (44.0)	16 (61.5)	49 (48.5)

^a α-Blocker treatment-experienced patients who had been under treatment with an α-blocker for at least 6 weeks at baseline. α-Blocker treatment-naïve patients who were to start α-blocker treatment simultaneously with solifenacin at baseline.

SD: standard deviation.

Table 2. Patients using solifenacin and α-blocker at 2, 4 and 6 months (safety analysis set).

Time point	Still usingmedication?	α-Blockertreatment naïve^an = 75	α-Blockertreatmentexperienced^an = 26	Totaln = 101
Solifenacin
2 months	No	4	1	5
	Yes	38	13	51
4 months	No	6	1	7
	Yes	28	10	38
6 months	No	7	1	8
	Yes	24	8	32
α-Blocker
2 months	No	7	6	13
	Yes	32	5	37
4 months	No	7	5	12
	Yes	23	6	29
6 months	No	12	3	15
	Yes	16	4	20

NOTE: Due to missing data, the number of subjects at months 2, 4 and 6 may not add up to the number of subjects in the SAS.

^a α-Blocker treatment-experienced patients who had been under treatment with an α-blocker for at least 6 weeks at baseline. α-Blocker treatment-naïve patients who were to start α-blocker treatment simultaneously with solifenacin at baseline.

Figure 2. PPBC scores at baseline and months 2, 4 and 6 (full analysis set).

Figure 3. Transformed OAB-q SF symptom bother (A) and QoL (B) scores at baseline and months 2, 4 and 6 (full analysis set).

Figure 4. Summary of urgency episodes (A) and urge incontinence (B) from 24-h voiding diaries.

Figure 5. Total IPSS at baseline and months 2, 4 and 6.